What is Phibro Animal Health Corporation's earnings per share (EPS)?

Phibro Animal Health Corporation (PAHC) reported diluted earnings per share of $2.43 for fiscal year 2026. This represents a 104.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Phibro Animal Health Corporation (PAHC) Financials

PAHC

FY2026 annual

Revenue $1.5B +17.1% YoY

Net Income $99.7M +106.6% YoY

EPS (Diluted) $2.43 +104.2% YoY

Free Cash Flow $9.9M -76.4% YoY

Market Cap $1.5B as of Sep 14, 2026

Price / Sales 1.0x on $1.5B revenue, FY2026

Price / Earnings 14.6x on $99.7M net income, FY2026

Price / Book 3.8x on $385.5M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 26, 2026 Currency USD FYE June

Newest figures come from the 10-K for FY2026, filed Aug 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PAHC SEC filings page.

Phibro Animal Health Corporation (PAHC) reported $1.5B in revenue for fiscal year 2026, up 17.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PAHC FY2026 2026-08-26

Margin expansion is the dominant mechanic, but reinvestment and working capital absorb much of the operating improvement.

Earnings quality weakened in FY2026: net income reached $99.7M, but operating cash flow was only $69.0M. Against FY2025, free cash flow fell to $9.9M as capital expenditures rose to $59.1M, leaving less accounting profit available after reinvestment.

Gross margin expanded from 30.9% to 33.8% between FY2025 and FY2026, indicating a more favorable profit mix or cost structure. Operating margin also rose from 8.5% to 12.8%, so the added gross profit was not fully consumed by overhead.

Inventory rose to $534.9M in FY2026, while receivables reached $238.8M; working capital became a larger cash absorber alongside growth. Debt-to-equity increased from 2.2x to 2.9x, even as short-term liquidity remained broadly stable.

Financial Health Signals

Financial Health Score 60/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Phibro Animal Health Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Phibro Animal Health Corporation has an operating margin of 12.8%, meaning the company retains $13 of operating profit per $100 of revenue. This strong profitability earns a score of 67/100, reflecting efficient cost management and pricing power. This is up from 8.5% the prior year.

Growth

Phibro Animal Health Corporation's revenue surged 17.1% year-over-year to $1.5B, reflecting rapid business expansion. This strong growth earns a score of 84/100.

Leverage

Phibro Animal Health Corporation has elevated debt relative to equity (D/E of 2.89), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 22/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.96, Phibro Animal Health Corporation holds $2.96 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

While Phibro Animal Health Corporation generated $69.0M in operating cash flow, capex of $59.1M consumed most of it, leaving $9.9M in free cash flow. This results in a low score of 34/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Phibro Animal Health Corporation earns a strong 25.9% return on equity (ROE), meaning it generates $26 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100. This is up from 16.9% the prior year.

Altman Z-Score Safe

3.05

Phibro Animal Health Corporation scores 3.05, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/7

Phibro Animal Health Corporation passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.69x

For every $1 of reported earnings, Phibro Animal Health Corporation generates $0.69 in operating cash flow ($69.0M OCF vs $99.7M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Adequate

4.19x

Phibro Animal Health Corporation earns $4.19 in operating income for every $1 of interest expense ($194.4M vs $46.4M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$396.7M

YoY+4.8%

QoQ+3.4%

5Y CAGR+12.5%

10Y CAGR+7.7%

Phibro Animal Health Corporation generated $396.7M in revenue in Q4 2026. This represents an increase of 4.8% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.

EBITDA

$61.5M

YoY+33.3%

QoQ+7.7%

5Y CAGR+17.9%

10Y CAGR+8.6%

Phibro Animal Health Corporation's EBITDA was $61.5M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 33.3% from the same quarter a year earlier. Against the prior quarter it is up 7.7%.

Net Income

$21.7M

YoY+26.0%

QoQ-9.6%

5Y CAGR+4.9%

10Y CAGR+3.6%

Phibro Animal Health Corporation reported $21.7M in net income in Q4 2026. This represents an increase of 26.0% from the same quarter a year earlier. Against the prior quarter it is down 9.6%.

EPS (Diluted)

$0.53

YoY+23.3%

QoQ-10.2%

5Y CAGR+4.8%

10Y CAGR+3.4%

Phibro Animal Health Corporation earned $0.53 per diluted share (EPS) in Q4 2026. This represents an increase of 23.3% from the same quarter a year earlier. Against the prior quarter it is down 10.2%.

Cash & Balance Sheet

Free Cash Flow

$5.2M

YoY-35.7%

QoQ+487.1%

10Y CAGR-12.1%

Phibro Animal Health Corporation generated $5.2M in free cash flow in Q4 2026, representing cash available after capex. This represents a decrease of 35.7% from the same quarter a year earlier. Against the prior quarter it is up 487.1%.

Cash & Debt

$61.4M

YoY-9.7%

QoQ+11.8%

5Y CAGR+4.1%

10Y CAGR+6.2%

Phibro Animal Health Corporation held $61.4M in cash as of Q4 2026; long-term debt is not reported for that period.

Dividends Per Share

Not reported for Q4 2026.

Shares Outstanding

Not reported for Q4 2026.

Margins & Returns

Gross Margin

33.9%

YoY+4.8pp

QoQ+1.1pp

5Y change+2.2pp

10Y change+2.4pp

Phibro Animal Health Corporation's gross margin was 33.9% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Operating Margin

12.1%

YoY+3.2pp

QoQ+0.5pp

5Y change+3.4pp

10Y change+1.5pp

Phibro Animal Health Corporation's operating margin was 12.1% in Q4 2026, reflecting core business profitability. This is up 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Net Margin

5.5%

YoY+0.9pp

QoQ-0.8pp

5Y change-2.3pp

10Y change-2.6pp

Phibro Animal Health Corporation's net profit margin was 5.5% in Q4 2026, showing the share of revenue converted to profit. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.

Return on Equity

5.6%

YoY-0.4pp

QoQ-1.0pp

5Y change-1.6pp

10Y change-11.2pp

Phibro Animal Health Corporation's ROE was 5.6% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.

Capital Allocation

Capital Expenditures

$18.9M

YoY+43.6%

QoQ+23.2%

5Y CAGR+21.6%

10Y CAGR+9.4%

Phibro Animal Health Corporation invested $18.9M in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 43.6% from the same quarter a year earlier. Against the prior quarter it is up 23.2%.

R&D Spending

Not reported for Q4 2026.

Share Buybacks

Not reported for Q4 2026.

PAHC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PAHC quarterly income statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$1.5B+17.1%	$1.3B+27.4%	$1.0B+4.1%	$977.9M+3.8%	$942.3M+13.1%	$833.4M+4.1%	$800.4M-3.3%	$828.0M+1.0%	$820.0M+7.3%	$764.3M+1.7%	$751.5M+0.4%	$748.6M+8.2%	$691.9M+5.9%	$653.2M-0.1%	$654.1M
Cost of Revenue	$1.0B+12.2%	$896.3M+27.2%	$704.6M+3.7%	$679.7M+3.5%	$656.9M+16.9%	$562.0M+3.4%	$543.5M-3.5%	$563.4M+1.9%	$553.1M+7.2%	$516.0M+0.7%	$512.5M-0.5%	$515.3M+5.7%	$487.5M+2.8%	$474.2M-3.2%	$490.0M
Gross Profit	$512.5M+28.1%	$399.9M+27.7%	$313.1M+5.0%	$298.2M+4.5%	$285.4M+5.2%	$271.4M+5.6%	$256.9M-2.9%	$264.6M-0.8%	$266.9M+7.5%	$248.2M+3.9%	$239.0M+2.5%	$233.3M+14.1%	$204.4M+14.2%	$179.0M+9.0%	$164.1M
R&D Expenses	$24.6M+3.5%	$23.7M-18.7%	$29.2M+19.7%	$24.4M+17.1%	$20.8M+17.3%	$17.8M+29.3%	$13.7M+13.6%	$12.1M+21.0%	$10.0M+5.9%	$9.4M-14.4%	$11.0M+16.0%	$9.5M+15.8%	$8.2M+23.7%	$6.6M-7.7%	$7.2M
SG&A Expenses	$318.1M+9.9%	$289.5M+11.4%	$259.8M+14.7%	$226.4M+9.7%	$206.4M+5.0%	$196.5M+4.7%	$187.7M+3.5%	$181.4M+8.0%	$168.0M+11.7%	$150.3M-1.9%	$153.3M+5.3%	$145.6M+3.5%	$140.6M+15.0%	$122.2M+6.5%	$114.8M
Operating Income	$194.4M+76.0%	$110.5M+107.2%	$53.3M-25.8%	$71.8M-9.0%	$79.0M+5.5%	$74.9M+8.2%	$69.2M-16.9%	$83.2M-15.9%	$98.9M+1.0%	$97.9M+14.2%	$85.7M-2.2%	$87.7M+37.4%	$63.8M+12.4%	$56.7M+15.0%	$49.3M
EBITDA	$245.9M+57.6%	$156.1M+74.4%	$89.5M-15.5%	$105.9M-5.2%	$111.7M+4.6%	$106.8M+5.1%	$101.5M-8.4%	$110.8M-12.0%	$125.9M+1.6%	$123.9M+13.5%	$109.2M-0.1%	$109.3M+28.2%	$85.2M+12.5%	$75.8M+13.3%	$66.9M
Interest Expense	$46.4M+24.7%	$37.2M+61.8%	$23.0M+23.2%	$18.7M+47.2%	$12.7M-7.5%	$13.7M-6.1%	$14.6M+6.8%	$13.7M+0.5%	$13.6M-19.4%	$16.9M+0.1%	$16.8M+15.8%	$14.6M-51.3%	$29.9M-4.8%	$31.4M-0.2%	$31.4M
Income Tax	$37.6M+90.7%	$19.7M+132.1%	$8.5M-60.4%	$21.5M-7.3%	$23.2M+91.6%	$12.1M-45.0%	$22.0M+30.8%	$16.8M-27.6%	$23.2M+45.6%	$15.9M+366.9%	-$6.0M-132.3%	$18.5M+95.9%	$9.4M+234.0%	-$7.0M-214.7%	$6.1M
Net Income	$99.7M+106.6%	$48.3M+1897.7%	$2.4M-92.6%	$32.6M-33.7%	$49.2M-9.6%	$54.4M+62.1%	$33.6M-38.7%	$54.7M-15.7%	$64.9M+0.4%	$64.6M-21.9%	$82.7M+37.2%	$60.3M+2027.7%	-$3.1M-112.6%	$24.9M+256.8%	$7.0M
EPS (Basic)	$2.46+106.7%	$1.19+1883.3%	$0.06-92.6%	$0.81-33.1%	$1.21-9.7%	$1.34+61.4%	$0.83-38.5%	$1.35-16.1%	$1.61-1.2%	$1.63-22.7%	$2.11+36.1%	$1.55+1650.0%	-$0.10-112.2%	$0.82	N/A
EPS (Diluted)	$2.43+104.2%	$1.19+1883.3%	$0.06-92.6%	$0.81-33.1%	$1.21-9.7%	$1.34+61.4%	$0.83-38.5%	$1.35-16.1%	$1.610.0%	$1.61-22.2%	$2.07+37.1%	$1.51+1610.0%	-$0.10-112.2%	$0.82	N/A
Diluted Shares (Avg)	41M+0.7%	41M+0.4%	41M0.0%	41M0.0%	41M0.0%	41M0.0%	41M+99853.1%	40,523+0.3%	40,385+0.9%	40,042+0.2%	39,962-99.9%	40M+23.7%	32M+105596.4%	30,458	N/A

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Revenue	$396.7M+4.8%	$383.5M+10.3%	$373.9M+20.9%	$363.9M+39.7%	$378.7M+38.6%	$347.8M+32.1%	$309.3M+23.7%	$260.4M+12.6%
Cost of Revenue	$262.3M-2.4%	$257.9M+6.0%	$241.3M+16.3%	$244.1M+38.0%	$268.7M+44.4%	$243.3M+32.5%	$207.4M+21.0%	$176.9M+8.1%
Gross Profit	$134.4M+22.2%	$125.7M+20.2%	$132.7M+30.2%	$119.8M+43.5%	$110.0M+26.2%	$104.6M+31.4%	$101.9M+29.6%	$83.5M+23.3%
SG&A Expenses	$86.2M+13.0%	$81.0M+14.0%	$82.3M+7.9%	$68.5M+4.1%	$76.3M+11.0%	$71.1M+19.1%	$76.3M+21.3%	$65.8M-3.9%
Operating Income	$48.2M+42.8%	$44.7M+33.2%	$50.3M+97.1%	$51.3M+189.6%	$33.7M+83.1%	$33.5M+68.2%	$25.5M+62.6%	$17.7M+2537.9%
EBITDA	$61.5M+33.3%	$57.1M+23.8%	$63.2M+70.4%	$64.1M+140.0%	$46.1M+67.0%	$46.1M+58.4%	$37.1M+50.8%	$26.7M+227.8%
Interest Expense	$10.7M+18.6%	$10.7M+10.6%	$12.5M+27.6%	$12.5M+43.1%	$9.0M+50.5%	$9.7M+71.0%	$9.8M+70.9%	$8.8M+55.3%
Income Tax	$10.6M+60.5%	$8.3M-5.9%	$9.0M+442.4%	$9.7M+268.2%	$6.6M+17.1%	$8.8M+95.0%	$1.7M-27.8%	$2.6M+166.7%
Net Income	$21.7M+26.0%	$24.0M+15.1%	$27.5M+762.1%	$26.5M+280.3%	$17.2M+2190.4%	$20.9M+148.4%	$3.2M+150.0%	$7.0M+187.0%
EPS (Basic)	$0.54+28.6%	$0.59+13.5%	$0.68+750.0%	$0.65+282.4%	$0.42+2000.0%	$0.52+147.6%	$0.08+166.7%	$0.17+185.0%
EPS (Diluted)	$0.53+23.3%	$0.59+15.7%	$0.67+737.5%	$0.65+282.4%	$0.43+2050.0%	$0.51+142.9%	$0.08+166.7%	$0.17+185.0%
Diluted Shares (Avg)	N/A	41M+0.8%	41M+0.6%	41M+0.7%	N/A	41M+0.5%	41M+0.5%	41M+0.2%

Not reported in any period shown, so not listed: R&D Expenses.

PAHC Balance Sheet

PAHC quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$1.5B+10.3%	$1.4B+38.6%	$982.2M+1.1%	$971.4M+4.3%	$931.7M+10.7%	$841.3M+7.3%	$784.1M+7.9%	$726.7M+8.2%	$671.7M+7.7%	$623.4M+2.6%	$607.8M+23.2%	$493.3M+4.4%	$472.3M-0.4%	$474.1M	N/A
Current Assets	$935.5M+15.4%	$810.6M+34.9%	$601.0M+2.6%	$585.7M+3.4%	$566.2M+13.5%	$498.9M+10.4%	$451.8M-3.1%	$466.2M+12.2%	$415.5M+14.2%	$363.7M+6.1%	$342.8M+9.3%	$313.7M+4.8%	$299.3M+1.0%	$296.4M	N/A
Cash & Equivalents	$61.4M-9.7%	$68.0M-3.6%	$70.6M+71.1%	$41.3M-44.4%	$74.2M+47.9%	$50.2M+38.2%	$36.3M-36.9%	$57.6M+97.4%	$29.2M-48.0%	$56.1M+66.9%	$33.6M+15.0%	$29.2M+147.2%	$11.8M-56.8%	$27.4M-49.2%	$53.9M
Short-Term Investments	$20.6M+128.6%	$9.0M-79.5%	$44.0M+10.0%	$40.0M+135.3%	$17.0M-60.5%	$43.0M-21.8%	$55.0M+129.2%	$24.0M-52.0%	$50.0M	$0	$0	$0	$0	$0	$0
Inventory	$534.9M+20.4%	$444.4M+67.1%	$265.9M-4.2%	$277.6M+7.1%	$259.2M+19.8%	$216.3M+10.0%	$196.7M-0.8%	$198.3M+11.3%	$178.2M+10.5%	$161.2M-3.9%	$167.7M+12.0%	$149.8M+4.6%	$143.2M+2.3%	$140.0M	N/A
Accounts Receivable	$238.8M+4.7%	$228.0M+34.5%	$169.5M+3.7%	$163.5M-1.8%	$166.5M+13.4%	$146.9M+16.1%	$126.5M-20.4%	$159.0M+17.2%	$135.7M+7.9%	$125.8M+1.7%	$123.8M+11.4%	$111.1M-2.4%	$113.9M+14.8%	$99.1M	N/A
Long-Term Investments	$8.8M+70.3%	$5.1M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$60.0M+0.7%	$59.6M+9.3%	$54.6M+2.4%	$53.3M+0.1%	$53.2M+1.0%	$52.7M0.0%	$52.7M+92.6%	$27.3M0.0%	$27.3M+14.0%	$24.0M+13.5%	$21.1M+67.5%	$12.6M0.0%	$12.6M0.0%	$12.6M+634.6%	$1.7M
Total Liabilities	$1.1B+3.8%	$1.1B+48.2%	$725.5M+5.3%	$688.9M+2.9%	$669.3M+11.0%	$602.8M+1.2%	$595.9M+16.7%	$510.7M+4.9%	$486.7M+3.1%	$472.2M-8.7%	$517.4M+11.6%	$463.7M+1.4%	$457.2M-15.8%	$543.1M	N/A
Current Liabilities	$316.5M+7.8%	$293.5M+43.8%	$204.1M+16.0%	$176.0M-7.8%	$190.8M+16.3%	$164.1M+4.4%	$157.2M+2.0%	$154.2M+7.7%	$143.2M+23.7%	$115.8M+6.5%	$108.8M-2.3%	$111.3M-1.0%	$112.4M-2.6%	$115.4M	N/A
Non-Current Liabilities	$799.3M+2.2%	$781.7M+49.9%	$521.4M+1.7%	$512.9M+7.2%	$478.4M+9.1%	$438.7M0.0%	$438.7M+23.1%	$356.4M+3.8%	$343.5M-3.6%	$356.4M-12.8%	$408.6M+16.0%	$352.4M+2.2%	$344.7M-19.4%	$427.7M	N/A
Long-Term Debt	N/A	$615.4M+118.0%	$282.3M-9.4%	$311.5M+14.1%	$272.9M-8.1%	$297.1M+36.3%	$218.0M+0.2%	$217.6M-5.3%	$229.8M-5.0%	$241.9M-13.1%	$278.3M-1.9%	$283.7M-0.9%	$286.4M-3.8%	$297.7M	N/A
Total Equity	$385.5M+34.9%	$285.7M+11.3%	$256.6M-9.2%	$282.5M+7.6%	$262.4M+10.0%	$238.5M+26.7%	$188.2M-12.9%	$216.0M+16.8%	$185.0M+22.4%	$151.2M+67.1%	$90.5M+205.4%	$29.6M+95.6%	$15.1M+122.0%	-$68.9M+21.9%	-$88.2M
Retained Earnings	$353.0M+29.4%	$272.7M+11.8%	$243.9M-6.5%	$260.9M+5.3%	$247.7M+13.6%	$218.0M+19.1%	$183.1M+8.4%	$168.9M+28.4%	$131.6M+59.0%	$82.8M+143.7%	$34.0M+191.9%	-$37.0M+62.0%	-$97.2M-3.3%	-$94.1M	N/A

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Total Assets	$1.5B+10.3%	$1.4B+9.7%	$1.4B+9.3%	$1.4B+43.4%	$1.4B+38.6%	$1.3B+34.5%	$1.3B+32.2%	$966.3M+0.2%
Current Assets	$935.5M+15.4%	$894.1M+15.2%	$862.2M+15.6%	$835.8M+46.4%	$810.6M+34.9%	$776.0M+29.9%	$746.2M+27.2%	$570.8M-2.3%
Cash & Equivalents	$61.4M-9.7%	$54.9M-9.0%	$55.5M-17.3%	$72.8M+40.4%	$68.0M-3.6%	$60.4M+20.2%	$67.1M+103.4%	$51.8M+20.1%
Short-Term Investments	$20.6M+128.6%	$22.5M+125.2%	$19.0M	$12.5M-67.1%	$9.0M-79.5%	$10.0M-79.4%	$0-100.0%	$38.0M-20.8%
Inventory	$534.9M+20.4%	$539.7M+20.4%	$517.3M+21.1%	$471.8M+73.1%	$444.4M+67.1%	$448.4M+58.8%	$427.2M+49.0%	$272.6M-2.4%
Accounts Receivable	$238.8M+4.7%	$221.5M+12.2%	$215.9M+12.6%	$217.9M+35.5%	$228.0M+34.5%	$197.5M+22.6%	$191.8M+27.3%	$160.8M+7.7%
Long-Term Investments	$8.8M+70.3%	$8.3M	$8.7M	$8.3M	$5.1M	$0	$0	$0
Goodwill	$60.0M+0.7%	$59.9M+9.7%	$59.8M+9.7%	$59.7M+9.4%	$59.6M+9.3%	$54.6M-0.1%	$54.5M-0.2%	$54.6M+2.5%
Total Liabilities	$1.1B+3.8%	$1.1B+3.0%	$1.1B+3.3%	$1.1B+51.7%	$1.1B+48.2%	$1.1B+48.3%	$1.0B+48.0%	$707.8M+2.4%
Current Liabilities	$316.5M+7.8%	$281.9M+5.8%	$282.4M+21.1%	$270.1M+52.7%	$293.5M+43.8%	$266.5M+40.9%	$233.3M+24.2%	$176.9M+2.6%
Non-Current Liabilities	$799.3M+2.2%	$801.4M+2.1%	$790.8M-1.8%	$803.7M+51.4%	$781.7M+49.9%	$784.8M+51.0%	$805.5M+56.7%	$530.9M+2.3%
Long-Term Debt	N/A	$597.7M-3.5%	$603.6M-3.1%	$609.5M+111.9%	$615.4M+118.0%	$619.2M+112.8%	$622.9M+109.1%	$287.7M-5.6%
Total Equity	$385.5M+34.9%	$361.8M+36.0%	$332.4M+34.7%	$311.7M+20.6%	$285.7M+11.3%	$266.0M-1.5%	$246.8M-8.9%	$258.5M-5.3%
Retained Earnings	$353.0M+29.4%	$336.1M+29.1%	$317.0M+29.7%	$294.4M+19.7%	$272.7M+11.8%	$260.3M+5.0%	$244.3M-0.1%	$246.0M-0.8%

PAHC Cash Flow Statement

PAHC quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$69.0M-13.9%	$80.1M-8.5%	$87.6M+558.1%	$13.3M-57.9%	$31.6M-34.5%	$48.3M-18.6%	$59.3M+25.8%	$47.2M-32.6%	$70.0M-28.8%	$98.4M+164.3%	$37.2M-45.8%	$68.7M+9749.4%	-$712K-149.5%	$1.4M-95.5%	$32.0M
Depreciation & Amortization	$51.5M+13.0%	$45.6M+26.1%	$36.2M+6.4%	$34.0M+4.0%	$32.7M+2.6%	$31.9M-1.4%	$32.3M+17.3%	$27.6M+2.3%	$26.9M+3.6%	$26.0M+10.9%	$23.5M+8.6%	$21.6M+0.7%	$21.5M+12.8%	$19.0M+8.5%	$17.5M
Stock-Based Compensation	$1.6M+122.7%	$717K+50.9%	$475K	N/A	N/A	$1.1M-50.0%	$2.3M0.0%	$2.3M+576.3%	$334K	$0	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	$59.1M+54.3%	$38.3M-7.1%	$41.2M-20.4%	$51.8M+39.8%	$37.0M+26.3%	$29.3M-13.9%	$34.0M+13.9%	$29.9M+61.2%	$18.5M-11.2%	$20.9M-42.6%	$36.4M+81.2%	$20.1M+1.1%	$19.8M-0.5%	$19.9M+34.6%	$14.8M
Free Cash Flow	$9.9M-76.4%	$41.8M-9.8%	$46.4M+220.5%	-$38.5M-613.3%	-$5.4M-128.4%	$19.0M-25.0%	$25.3M+46.4%	$17.3M-66.4%	$51.5M-33.6%	$77.5M+8849.8%	$866K-98.2%	$48.6M+336.6%	-$20.6M-11.1%	-$18.5M-207.8%	$17.2M
Investing Cash Flow	-$71.5M+75.2%	-$288.7M-499.0%	-$48.2M+34.9%	-$74.0M-227.8%	-$22.6M-21.5%	-$18.6M+84.6%	-$120.4M-751.8%	-$14.1M+83.3%	-$84.6M-285.6%	-$21.9M+73.5%	-$82.8M	N/A	N/A	N/A	N/A
Financing Cash Flow	-$6.6M-103.2%	$207.1M+3160.5%	-$6.8M-125.1%	$27.0M+65.1%	$16.3M+196.2%	-$17.0M-141.5%	$40.9M+1096.7%	-$4.1M+65.1%	-$11.8M+78.1%	-$53.7M-206.7%	$50.4M	N/A	N/A	N/A	N/A
Dividends Paid	$19.5M+0.1%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M+0.1%	$19.4M+0.1%	$19.4M+4.4%	$18.6M+15.7%	$16.1M+1.6%	$15.8M+0.8%	$15.7M+0.7%	$15.6M-37.6%	$25.0M+733.3%	$3.0M	N/A

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Operating Cash Flow	$24.1M+13.3%	$16.2M-62.4%	$19.4M+529.1%	$9.3M-26.3%	$21.3M-25.2%	$43.2M+278.3%	$3.1M-90.3%	$12.6M-22.1%
Depreciation & Amortization	$13.3M+7.5%	$12.4M-1.3%	$12.9M+11.4%	$12.8M+42.5%	$12.4M+34.9%	$12.6M+37.2%	$11.6M+29.9%	$9.0M+1.5%
Stock-Based Compensation	N/A	N/A	N/A	$339K+89.4%	N/A	N/A	N/A	$179K+121.0%
Capital Expenditures	$18.9M+43.6%	$15.3M+97.7%	$11.1M+41.9%	$13.8M+44.1%	$13.1M+0.5%	$7.7M-20.4%	$7.8M-28.6%	$9.6M+28.2%
Free Cash Flow	$5.2M-35.7%	$890K-97.5%	$8.3M+273.9%	-$4.5M-248.2%	$8.1M-47.1%	$35.4M+2011.4%	-$4.7M-123.0%	$3.0M-65.2%
Investing Cash Flow	-$16.5M-133.9%	-$16.8M+7.9%	-$17.2M+93.4%	-$21.0M-617.2%	-$7.0M+22.8%	-$18.3M-1715.1%	-$260.5M-947.7%	-$2.9M+80.9%
Financing Cash Flow	-$1.6M+79.2%	-$2.3M+92.9%	-$19.0M-106.9%	$16.3M+155.9%	-$7.8M-534.6%	-$32.2M-763.8%	$276.3M+1979.1%	-$29.2M-2352.9%
Dividends Paid	$4.9M+0.1%	$4.9M+0.1%	$4.9M+0.1%	$4.9M+0.1%	$4.9M+0.1%	$4.9M+0.1%	$4.9M0.0%	$4.9M0.0%

Not reported in any period shown, so not listed: Share Buybacks.

PAHC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PAHC quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	33.8%+2.9pp	30.9%+0.1pp	30.8%+0.3pp	30.5%+0.2pp	30.3%-2.3pp	32.6%+0.5pp	32.1%+0.1pp	32.0%-0.6pp	32.6%+0.1pp	32.5%+0.7pp	31.8%+0.7pp	31.2%+1.6pp	29.5%+2.1pp	27.4%+2.3pp	25.1%
Operating Margin	12.8%+4.3pp	8.5%+3.3pp	5.2%-2.1pp	7.3%-1.0pp	8.4%-0.6pp	9.0%+0.3pp	8.6%-1.4pp	10.1%-2.0pp	12.1%-0.7pp	12.8%+1.4pp	11.4%-0.3pp	11.7%+2.5pp	9.2%+0.5pp	8.7%+1.2pp	7.5%
Net Margin	6.6%+2.8pp	3.7%+3.5pp	0.2%-3.1pp	3.3%-1.9pp	5.2%-1.3pp	6.5%+2.3pp	4.2%-2.4pp	6.6%-1.3pp	7.9%-0.5pp	8.5%-2.6pp	11.0%+3.0pp	8.1%+8.5pp	-0.4%-4.3pp	3.8%+2.7pp	1.1%
Return on Equity	25.9%+9.0pp	16.9%+16.0pp	0.9%-10.6pp	11.5%-7.2pp	18.7%-4.1pp	22.8%+5.0pp	17.8%-7.5pp	25.3%-9.7pp	35.1%-7.7pp	42.8%-48.7pp	91.4%-112.0pp	203.5%+224.1pp	-20.6%	N/A	N/A
Return on Assets	6.6%+3.1pp	3.5%+3.3pp	0.3%-3.1pp	3.4%-1.9pp	5.3%-1.2pp	6.5%+2.2pp	4.3%-3.3pp	7.5%-2.1pp	9.7%-0.7pp	10.4%-3.3pp	13.6%+1.4pp	12.2%+12.9pp	-0.7%-5.9pp	5.3%	N/A
Current Ratio	2.96+0.2x	2.76-0.2x	2.94-0.4x	3.33+0.4x	2.97-0.1x	3.04+0.2x	2.87-0.1x	3.02+0.1x	2.90-0.2x	3.140.0x	3.15+0.3x	2.82+0.2x	2.66+0.1x	2.57	N/A
Debt-to-Equity	2.89+0.7x	2.15+1.1x	1.100.0x	1.10+0.1x	1.04-0.2x	1.25+0.1x	1.16+0.2x	1.01-0.2x	1.24-0.4x	1.60-1.5x	3.08-6.5x	9.58-9.3x	18.91	N/A	N/A
Asset Turnover	1.01+0.1x	0.95-0.1x	1.040.0x	1.010.0x	1.010.0x	0.990.0x	1.02-0.1x	1.14-0.1x	1.220.0x	1.230.0x	1.24-0.3x	1.52+0.1x	1.46+0.1x	1.38	N/A
FCF Margin	0.7%-2.6pp	3.2%-1.3pp	4.6%+8.5pp	-3.9%-3.4pp	-0.6%-2.9pp	2.3%-0.9pp	3.2%+1.1pp	2.1%-4.2pp	6.3%-3.9pp	10.1%+10.0pp	0.1%-6.4pp	6.5%+9.5pp	-3.0%-0.1pp	-2.8%-5.5pp	2.6%

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Gross Margin	33.9%+4.8pp	32.8%+2.7pp	35.5%+2.5pp	32.9%+0.9pp	29.0%-2.9pp	30.1%-0.2pp	32.9%+1.5pp	32.1%+2.8pp
Operating Margin	12.1%+3.2pp	11.6%+2.0pp	13.5%+5.2pp	14.1%+7.3pp	8.9%+2.2pp	9.6%+2.1pp	8.3%+2.0pp	6.8%+7.1pp
Net Margin	5.5%+0.9pp	6.3%+0.3pp	7.3%+6.3pp	7.3%+4.6pp	4.5%+4.3pp	6.0%+2.8pp	1.0%+0.5pp	2.7%+6.1pp
Return on Equity	5.6%-0.4pp	6.6%-1.2pp	8.3%+7.0pp	8.5%+5.8pp	6.0%+5.7pp	7.8%+4.7pp	1.3%+0.8pp	2.7%+5.6pp
Return on Assets	1.5%+0.2pp	1.7%+0.1pp	1.9%+1.7pp	1.9%+1.2pp	1.3%+1.2pp	1.6%+0.7pp	0.3%+0.1pp	0.7%+1.6pp
Current Ratio	2.96+0.2x	3.17+0.3x	3.05-0.1x	3.09-0.1x	2.76-0.2x	2.91-0.2x	3.20+0.1x	3.23-0.2x
Debt-to-Equity	2.89+0.7x	1.65-0.7x	1.82-0.7x	1.96+0.8x	2.15+1.1x	2.33+1.3x	2.52+1.4x	1.110.0x
Asset Turnover	0.260.0x	0.270.0x	0.270.0x	0.260.0x	0.280.0x	0.260.0x	0.240.0x	0.270.0x
FCF Margin	1.3%-0.8pp	0.2%-10.0pp	2.2%+3.7pp	-1.2%-2.4pp	2.1%-3.5pp	10.2%+9.5pp	-1.5%-9.8pp	1.2%-2.6pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Phibro Animal Health Corporation PAHC	FY2026	$1.5B	$99.7M	6.6%	$1.5B	60/100
BGM Group Ltd. BGM	FY2025	$37.9M	-$19.9M	-52.6%	$105.4M	28/100
Harrow, Inc. HROW	FY2025	$272.3M	-$5.1M	-1.9%	$1.3B	52/100
Avadel Pharmaceuticals plc AVDL	FY2024	$169.1M	-$48.8M	-28.9%	$2.1B	53/100
BioCryst Pharmaceuticals Inc BCRX	FY2025	$874.8M	$263.9M	30.2%	$2.1B	74/100
Amphastar Pharmaceuticals, Inc. AMPH	FY2025	$719.9M	$98.1M	13.6%	$1.0B	70/100

Where Phibro Animal Health Corporation Ranks

Frequently Asked Questions

What is Phibro Animal Health Corporation's annual revenue?

Phibro Animal Health Corporation (PAHC) reported $1.5B in total revenue for fiscal year 2026. This represents a 17.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Phibro Animal Health Corporation's revenue growing?

Phibro Animal Health Corporation (PAHC) revenue grew by 17.1% year-over-year, from $1.3B to $1.5B in fiscal year 2026.

Is Phibro Animal Health Corporation profitable?

Yes, Phibro Animal Health Corporation (PAHC) reported a net income of $99.7M in fiscal year 2026, with a net profit margin of 6.6%.

What is Phibro Animal Health Corporation's EBITDA?

Phibro Animal Health Corporation (PAHC) had EBITDA of $245.9M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Phibro Animal Health Corporation's gross margin?

Phibro Animal Health Corporation (PAHC) had a gross margin of 33.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Phibro Animal Health Corporation's operating margin?

Phibro Animal Health Corporation (PAHC) had an operating margin of 12.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Phibro Animal Health Corporation's net profit margin?

Phibro Animal Health Corporation (PAHC) had a net profit margin of 6.6% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Does Phibro Animal Health Corporation pay dividends?

Yes, Phibro Animal Health Corporation (PAHC) paid $0.48 per share in dividends during fiscal year 2026.

What is Phibro Animal Health Corporation's return on equity (ROE)?

Phibro Animal Health Corporation (PAHC) has a return on equity of 25.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Phibro Animal Health Corporation's free cash flow?

Phibro Animal Health Corporation (PAHC) generated $9.9M in free cash flow during fiscal year 2026. This represents a -76.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Phibro Animal Health Corporation's operating cash flow?

Phibro Animal Health Corporation (PAHC) generated $69.0M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Phibro Animal Health Corporation's total assets?

Phibro Animal Health Corporation (PAHC) had $1.5B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Phibro Animal Health Corporation's capital expenditures?

Phibro Animal Health Corporation (PAHC) invested $59.1M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Phibro Animal Health Corporation spend on research and development?

Phibro Animal Health Corporation (PAHC) invested $24.6M in research and development during fiscal year 2026.

What is Phibro Animal Health Corporation's current ratio?

Phibro Animal Health Corporation (PAHC) had a current ratio of 2.96 as of fiscal year 2026, which is generally considered healthy.

What is Phibro Animal Health Corporation's debt-to-equity ratio?

Phibro Animal Health Corporation (PAHC) had a debt-to-equity ratio of 2.89 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Phibro Animal Health Corporation's return on assets (ROA)?

Phibro Animal Health Corporation (PAHC) had a return on assets of 6.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Phibro Animal Health Corporation's P/E ratio?

Phibro Animal Health Corporation (PAHC) trades at 14.6x earnings, its market capitalization divided by net income of $99.7M net income, FY2026. The market capitalization is $1.5B as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Phibro Animal Health Corporation's price-to-sales ratio?

Phibro Animal Health Corporation (PAHC) trades at 1.0x sales, its market capitalization divided by revenue of $1.5B revenue, FY2026. The market capitalization is $1.5B as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Phibro Animal Health Corporation's Altman Z-Score?

Phibro Animal Health Corporation (PAHC) has an Altman Z-Score of 3.05, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Phibro Animal Health Corporation's Piotroski F-Score?

Phibro Animal Health Corporation (PAHC) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Phibro Animal Health Corporation's earnings high quality?

Phibro Animal Health Corporation (PAHC) has an earnings quality ratio of 0.69x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Phibro Animal Health Corporation cover its interest payments?

Phibro Animal Health Corporation (PAHC) has an interest coverage ratio of 4.19x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Phibro Animal Health Corporation?

Phibro Animal Health Corporation (PAHC) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.